Unknown
PHASE2
INTERVENTIONAL
NCT04869371
Androgen Deprivation Therapy Combined With Docetaxel for High Risk Prostate Cancer
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
This randomized, controlled, single center clinical trial aims to evaluate the efficacy and safety of Androgen Deprivation Therapy Combined with Docetaxel for High Risk Prostate Cancer with a six-month treatment cycle.
Interventions
Name:
Docetaxel injection
Type:
DRUG
Description:
75 mg/m2 body surface area every 3 weeks for 6 cycles before robot assisted radical prostatectomy
Name:
Triptorelin Pamoate for Injectable Suspension
Type:
DRUG
Description:
15mg every 12 weeks
Name:
Prednisone Acetate Tablets
Type:
DRUG
Description:
5 mg oral low dose prednisone, once daily
Primary Outcomes
Measure:
Pathologic Complete Response Rate
TimeFrame:
up to 8 months
Description:
The proportion of subjects with no morphologically recognizable cancer cell in tumor specimens after radical prostatectomy.
Measure:
pCR or MRD rate
TimeFrame:
up to 8 months
Description:
The proportion of patients with pCR or MRD. Pathologic complete response (pCR): defined as no morphologically recognizable cancer cell in tumor specimens after radical prostatectomy.
Minimal Residual Disease (MRD): defined as residual tumors with maximum diameter of 3 mm or less after radical prostatectomy.
Trial Information
NCT ID
NCT04869371
Status
Unknown
Study Type
INTERVENTIONAL
Phases
PHASE2
Sponsor
Hongqian Guo
Last Updated
December 15, 2025